Atlas Private Wealth Advisors Buys Shares of 284 Eli Lilly and Company $LLY

Atlas Private Wealth Advisors bought a new stake in Eli Lilly and Company (NYSE:LLY) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 284 shares of the company’s stock, valued at approximately $222,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after purchasing an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 2.2%

Shares of NYSE LLY opened at $862.96 on Friday. The firm has a market cap of $816.76 billion, a P/E ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The firm’s 50 day moving average price is $780.74 and its 200 day moving average price is $771.71. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter last year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Guggenheim reissued a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. JPMorgan Chase & Co. decreased their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Finally, Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $940.00.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.